Oh dear !!, page-45

Agree with you ex-boss.
I think Lonestar may move in above us and we'll sit above LVADs.
The qualifications I would have are very much on the positive side.
I think it is likely, ( Lonestar by their design of trial appears also to think it likely) they will have the problems of ACORN to some degree. Combined with C-Pulse, (we look after their morbidity they enhance our non super responders) I think they may form one of the combinAtion therapies we are expecting.
downstream we are moving into bridge to transplant so we will move in to LVAD territory and probably expand this market as well, beyond what LVADs have reached.
I think we get into a very special place with CP2, cheap, safe, easy to implant, rest heart, profuse heart, turn off emergency responses, little burden on patient.
First to market as well.
we're the only product that rests heart muscle and gets more blood to it.
Ie. Takes stress off heart muscle.
We're the strategic product in Class 2 to Class 4 ambulatory to build a suite of therapies / devices around and as such have a very nice future.